Difference between revisions of "Wilms tumor"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#4a1486"|'''Section editor''' |- |s...") |
|||
Line 41: | Line 41: | ||
# Wolff JA, Newton WA Jr, Krivit W, D'Angio GJ. Single versus multiple dose dactinomycin therapy of Wilms's tumor: a controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med. 1968 Aug 8;279(6):290-4. [https://www.nejm.org/doi/full/10.1056/NEJM196808082790605 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4298260 PubMed] | # Wolff JA, Newton WA Jr, Krivit W, D'Angio GJ. Single versus multiple dose dactinomycin therapy of Wilms's tumor: a controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med. 1968 Aug 8;279(6):290-4. [https://www.nejm.org/doi/full/10.1056/NEJM196808082790605 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4298260 PubMed] | ||
## '''Update:''' Wolff JA, D'Angio G, Hartmann J, Krivit W, Newton WA Jr. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor. N Engl J Med. 1974 Jan 10;290(2):84-6. [https://www.nejm.org/doi/full/10.1056/NEJM197401102900205 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/4357042 PubMed] | ## '''Update:''' Wolff JA, D'Angio G, Hartmann J, Krivit W, Newton WA Jr. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor. N Engl J Med. 1974 Jan 10;290(2):84-6. [https://www.nejm.org/doi/full/10.1056/NEJM197401102900205 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/4357042 PubMed] | ||
+ | |||
+ | ==Dactinomycin & Vincristine {{#subobject:3f9a1a|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen {{#subobject:d19340|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 25%"|Study | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|Comparator | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[https://www.sciencedirect.com/science/article/pii/S0140673604171390 de Kraker et al. 2004 (SIOP 93-01)] | ||
+ | | style="background-color:#1a9851" |Phase III (E) | ||
+ | |Prolonged chemotherapy | ||
+ | | style="background-color:#eeee01" |Equivalent EFS | ||
+ | |- | ||
+ | |} | ||
+ | ====Preceding treatment==== | ||
+ | *[[Surgery#Surgical_resection|Surgical resection]] | ||
+ | ====Chemotherapy==== | ||
+ | *[[Dactinomycin (Cosmegen)]] | ||
+ | *[[Vincristine (Oncovin)]] | ||
+ | |||
+ | ===References=== | ||
+ | # '''SIOP 93-01:''' de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. [https://www.sciencedirect.com/science/article/pii/S0140673604171390 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/15464183 PubMed] | ||
[[Category:Wilms' tumor regimens]] | [[Category:Wilms' tumor regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Pediatric cancers]] | [[Category:Pediatric cancers]] |
Revision as of 20:17, 10 December 2018
Section editor | |
---|---|
Wayne H. Liang, MD, MS Birmingham, AL Twitter: WayneLiangMD |
3 regimens on this page
3 variants on this page
|
All lines of therapy
Dactinomycin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Wolff et al. 1968 | Randomized (E) | Single course of dactinomycin | Seems to have superior RFS |
Preceding treatment
Chemotherapy
- Dactinomycin (Cosmegen) 15 mcg/kg IV once per day on days 1 to 5
6-week cycle for 3 cycles, then 3-month cycle for 4 cycles
References
- Wolff JA, Newton WA Jr, Krivit W, D'Angio GJ. Single versus multiple dose dactinomycin therapy of Wilms's tumor: a controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med. 1968 Aug 8;279(6):290-4. link to original article PubMed
- Update: Wolff JA, D'Angio G, Hartmann J, Krivit W, Newton WA Jr. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor. N Engl J Med. 1974 Jan 10;290(2):84-6. link to original article contains verified protocol PubMed
Dactinomycin & Vincristine
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
de Kraker et al. 2004 (SIOP 93-01) | Phase III (E) | Prolonged chemotherapy | Equivalent EFS |
Preceding treatment
Chemotherapy
References
- SIOP 93-01: de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. link to SD article PubMed